Regenxbio
RGNX
177 hedge funds and large institutions have $1.87B invested in Regenxbio in 2018 Q2 according to their latest regulatory filings, with 81 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 23 closing their positions.
252% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 23
180% more capital invested
Capital invested by funds: $668M → $1.87B (+$1.2B)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
55% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 33
48% more funds holding
Funds holding: 120 → 177 (+57)
44% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $10.6M
10.83% more ownership
Funds ownership: 70.66% → 81.49% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$95.4M |
| 2 |
WM
WS Management
Jacksonville,
Florida
|
+$40.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.8M |
| 5 |
HCM
Highline Capital Management
New York
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$35.6M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$27.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$23.7M |
| 4 |
JP Morgan Chase
New York
|
-$19M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.6M |
RGNX Hedge Fund Activity: Q2 2018 in Review
177 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2018, worth a combined $1.87B — up 180% from $668M a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new RGNX positions and 23 closed out — a net gain of 58 holders — while 51 added to existing stakes and 33 trimmed.
The largest buyer was BlackRock, adding an estimated $95.4M. The largest seller was Citadel Advisors, cutting an estimated $35.6M.
- 177 institutional investors held Regenxbio (RGNX) as of Q2 2018, up from 120 in Q1 2018.
- Funds reported $1.87B of Regenxbio stock for Q2 2018, up 180% quarter-over-quarter.
- 81 funds opened new Regenxbio positions in Q2 2018 and 23 closed out, a net change of +58 holders.
- The largest Regenxbio buyer in Q2 2018 was BlackRock, an estimated $95.4M added.
- The largest Regenxbio seller in Q2 2018 was Citadel Advisors, an estimated $35.6M sold.
Based on aggregated 13F filings for Q2 2018.